AdvisorShares Psychedelics ETF Rating $24.05 -1.00 (-3.99%) Closing price 09/23/2026 04:10 PM EasternExtended Trading$24.06 +0.00 (+0.02%) As of 09/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatings AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.68Holdings in PSIL have an aggregate rating of Moderate Buy based on 222 analyst ratings issued in the past year covering 19 companies (73.7% of the portfolio).PSIL Aggregate Price Target$24.05High Prediction$24.05Average Prediction$24.05Low Prediction$24.05Holdings in PSIL have an aggregate price target of $24.05 and a range of $24.05 to $24.05 covering 19 companies (73.7% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy11 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell2 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 PSIL Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings12.28%CMPSCompass Pathways$13.75-7.0%Moderate Buy$23.36 69.9%172.3839 of 5 stars10.58%DFTXDefinium Therapeutics$37.65-6.6%Buy$64.88 72.3%212.8817 of 5 stars4.91%STIMNeuronetics$2.88-1.0%Moderate Buy$4.67 62.0%53.4501 of 5 stars4.68%NRXPNRx Pharmaceuticals$3.16-4.8%Hold$34.50 991.8%71.452 of 5 stars4.58%GHRSGH Research$25.96-6.8%Moderate Buy$45.00 73.3%122.7117 of 5 stars4.46%NBIXNeurocrine Biosciences$139.49-1.9%Moderate Buy$201.09 44.2%244.7488 of 5 starsPositive News4.46%RLMDRelmada Therapeutics$3.78-10.8%Moderate Buy$12.00 217.5%81.8136 of 5 starsPositive News4.30%ABBVAbbVie$265.43+0.1%Moderate Buy$276.64 4.2%253.8324 of 5 starsTrending News4.23%ANROAlto Neuroscience$27.48-10.7%Moderate Buy$37.25 35.5%112.2143 of 5 stars4.00%JNJJohnson & Johnson$269.01-0.1%Moderate Buy$274.13 1.9%254.4069 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision3.61%ALKSAlkermes$42.13-2.7%Moderate Buy$54.75 30.0%183.509 of 5 starsTrending NewsAnalyst Forecast2.67%SUPNSupernus Pharmaceuticals$43.39-0.8%Hold$62.83 44.8%73.7458 of 5 starsAnalyst Forecast2.55%LLYEli Lilly and Company$1,153.69-1.4%Moderate Buy$1,305.25 13.1%304.7503 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision2.26%PBMPsyence Biomedical$6.31+3.4%Strong Sell11.3248 of 5 starsNews CoverageGap DownHigh Trading Volume1.99%NEUPNeuphoria Therapeutics$3.68-1.3%Reduce$7.00 90.2%32.2278 of 5 starsPositive News1.01%KTTAPasithea Therapeutics$0.51-0.3%Hold$3.00 485.1%32.3842 of 5 starsAnalyst Forecast0.46%IXHLIncannex Healthcare$3.44+1.5%Hold$18.00 423.3%21.6421 of 5 stars0.38%IGCIGC Pharma$0.29+1.1%Moderate Buy$5.50 1,822.4%23.0989 of 5 starsNews Coverage0.28%SILOSilo Pharma$1.77+2.9%Strong Sell11.0668 of 5 stars This page (NYSEARCA:PSIL) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredMy next big call (under $1)While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...Crypto 101 Media | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
